99 related articles for article (PubMed ID: 35399019)
1. [Value of tumor growth rate in evaluating the early therapeutic efficacy of neuroendocrine neoplasm].
Zhou YT; Xia YF; Li Y; Zhu YJ; Chi Y; Jiang L
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(14):1000-1006. PubMed ID: 35399019
[No Abstract] [Full Text] [Related]
2. Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study.
Lamarca A; Crona J; Ronot M; Opalinska M; Lopez Lopez C; Pezzutti D; Najran P; Carvhalo L; Franca Bezerra RO; Borg P; Vietti Violi N; Vidal Trueba H; de Mestier L; Schaefer N; Sundin A; Costa F; Pavel M; Dromain C;
Oncologist; 2019 Nov; 24(11):e1082-e1090. PubMed ID: 30910869
[TBL] [Abstract][Full Text] [Related]
3. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors.
Dromain C; Pavel ME; Ruszniewski P; Langley A; Massien C; Baudin E; Caplin ME;
BMC Cancer; 2019 Jan; 19(1):66. PubMed ID: 30642293
[TBL] [Abstract][Full Text] [Related]
4. [Clinicopathologic features and prognostic analysis of 240 patients with gastric neuroendocrine neoplasms].
Liang WQ; Zhang W; Qiao S; Wang BH; Wang C; Zhuang ZW; Xi HQ; Cai AZ; Wei B; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jan; 23(1):38-43. PubMed ID: 31958929
[No Abstract] [Full Text] [Related]
5. Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study.
Lamarca A; Ronot M; Moalla S; Crona J; Opalinska M; Lopez Lopez C; Pezzutti D; Najran P; Carvhalo L; Bezerra ROF; Borg P; Vietti Violi N; Vidal Trueba H; de Mestier L; Scaefer N; Baudin E; Sundin A; Costa F; Pavel M; Dromain C
Clin Cancer Res; 2019 Nov; 25(22):6692-6699. PubMed ID: 31375514
[TBL] [Abstract][Full Text] [Related]
6. Preoperative apolipoprotein B/A1 ratio is an independent prognostic factor in metastatic renal cell carcinoma.
Zhang F; Xie Y; Ma X; Gu L; Li H; Li X; Guo G; Zhang X
Urol Oncol; 2019 Mar; 37(3):184.e9-184.e17. PubMed ID: 30509867
[TBL] [Abstract][Full Text] [Related]
7. Tumor Growth Rate to Predict the Outcome of Patients with Neuroendocrine Tumors: Performance and Sources of Variability.
Dromain C; Sundin A; Najran P; Vidal Trueba H; Dioguardi Burgio M; Crona J; Opalinska M; Carvalho L; Franca R; Borg P; Vietti Violi N; Schaefer N; Lopez C; Pezzutti D; de Mestier L; Lamarca A; Costa F; Pavel M; Ronot M
Neuroendocrinology; 2021; 111(9):831-839. PubMed ID: 32717738
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of metabolic tumour volume on baseline
Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
[TBL] [Abstract][Full Text] [Related]
9. Five-year native liver survival analysis in biliary atresia from a single large Chinese center: The death/liver transplantation hazard change and the importance of rapid early clearance of jaundice.
Wang Z; Chen Y; Peng C; Pang W; Zhang T; Wu D; Shen Q; Li M
J Pediatr Surg; 2019 Aug; 54(8):1680-1685. PubMed ID: 30518490
[TBL] [Abstract][Full Text] [Related]
10. [Establishment and validation of a nomogram to predict overall survival of patients with gastric neuroendocrine neoplasms].
Wang YL; Guo Y; Zhang RH; Chen LH; Yang YJ; Wang W; Chen J; Zhou ZW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Oct; 24(10):883-888. PubMed ID: 34674463
[No Abstract] [Full Text] [Related]
11. Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.
Lamarca A; Barriuso J; Kulke M; Borbath I; Lenz HJ; Raoul JL; Meropol NJ; Lombard-Bohas C; Posey J; Faivre S; Raymond E; Valle JW
Br J Cancer; 2018 Jan; 118(2):181-188. PubMed ID: 29161241
[TBL] [Abstract][Full Text] [Related]
12. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.
Ferté C; Koscielny S; Albiges L; Rocher L; Soria JC; Iacovelli R; Loriot Y; Fizazi K; Escudier B
Eur Urol; 2014 Apr; 65(4):713-20. PubMed ID: 23993162
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation value of preoperative peripheral blood lymphocyte-to-monocyte ratio on the prognosis of patients with stage III colon cancer].
Chen J; Peng J; Fan W; Zhang R; Wang F; Zhou W; Xu D; Pan Z; Lu Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):73-78. PubMed ID: 30703797
[TBL] [Abstract][Full Text] [Related]
14. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L
Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of Tumor Growth Rate (TGR) in Patients with Huge Hepatocellular Carcinoma Undergoing Transcatheter Arterial Chemoembolization.
Chen G; Xie X; Wang M; Guo X; Zhang Z; Zhang L; Zhang B
Curr Oncol; 2022 Jan; 29(2):423-432. PubMed ID: 35200538
[TBL] [Abstract][Full Text] [Related]
16. The Diagnostic Value Of Using
Hua L; Hua F; Zhu H; Deng J; Wang D; Luan S; Tang H; Guan Y; Xie Q; Gong Y
Cancer Manag Res; 2019; 11():9185-9193. PubMed ID: 31802943
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis.
Bongiovanni A; Liverani C; Foca F; Fausti V; Di Menna G; Mercatali L; De Vita A; Riva N; Calpona S; Miserocchi G; Spadazzi C; Cocchi C; Ibrahim T
Neuroendocrinology; 2021; 111(9):895-906. PubMed ID: 33221806
[TBL] [Abstract][Full Text] [Related]
18. Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy.
He LN; Zhang X; Li H; Chen T; Chen C; Zhou Y; Lin Z; Du W; Fang W; Yang Y; Huang Y; Zhao H; Hong S; Zhang L
Front Oncol; 2020; 10():621329. PubMed ID: 33552993
[TBL] [Abstract][Full Text] [Related]
19. [Clinicopathological characteristics and prognosis analysis of colorectal neuroendocrine neoplasms based on the data from domestic six medical centers].
Zhang Y; Peng X; Jin K; Wang W; Feng X; Zeng Y; Chen M; Yu X; Chen Y; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1235-1240. PubMed ID: 27928792
[TBL] [Abstract][Full Text] [Related]
20. [Predictive value of log odds of positive lymph nodes for the prognosis of patients with node-negative squamous cell carcinoma of the thoracic esophagus after radical esophagectomy].
Yang M; Zhang H; Huo X; Chen C; Yu Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 May; 19(5):535-9. PubMed ID: 27215521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
